TWO US clinical investigator sites have been opened for a phase 1 clinical trial for patients with soft tissue sarcoma and the first patient has been dosed.
The issue of transparency in clinical research has raised its head again with a new study suggesting the results of Phase I trials are less likely to be published compared to other types of studies.
UK-based microdosing specialist Xceleron has announced its
expansion with the takeover of a new facility in the US, two years
after setting up a business base in the region.
Charles River Laboratories is the latest in a series of large
contract research organisations making acquisitions to beef up
their Phase I capacity as this market sector remains hot.